XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity
 6 Months Ended
Jun. 24, 2022
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Equity Awards

The following table reflects the activity of RSAs during the twenty-six weeks ended June 24, 2022:
Time-basedPerformance-basedMarket-based
SharesWeighted Average
Grant Date Fair Value		SharesWeighted Average
Grant Date Fair Value		SharesWeighted Average
Grant Date Fair Value
Unvested at December 24, 2021617,996 $28.33 187,437 $32.04 185,129 $31.44 
Granted154,822 27.32 167,261 32.44 167,261 29.12 
Vested(313,174)26.38 — — — — 
Forfeited(12,094)29.13 (14,001)32.14 (14,003)30.82 
Unvested at June 24, 2022447,550 $29.32 340,697 $32.23 338,387 $30.32 

The Company granted 489,344 RSAs to its employees and directors at a weighted average grant date fair value of $30.50 during the twenty-six weeks ended June 24, 2022. These awards are a mix of time-, market- and performance-based grants that generally vest over a range of periods up to four years. The Company recognized expense totaling $2,939 and $3,280 on its RSAs during the thirteen weeks ended June 24, 2022 and June 25, 2021, respectively, and $5,982 and $5,738 during the twenty-six weeks ended June 24, 2022 and June 25, 2021, respectively.

At June 24, 2022, the total unrecognized compensation cost for unvested RSAs was $23,850 and the weighted-average remaining period was approximately 2.2 years. Of this total, $11,916 related to RSAs with time-based vesting provisions and $11,934 related to RSAs with performance-based vesting provisions. At June 24, 2022, the weighted-average remaining period for time-based vesting and performance-based vesting RSAs were approximately 2.1 years and 2.2 years, respectively.

No share-based compensation expense related to the Company’s RSAs or stock options has been capitalized. As of June 24, 2022, there were 2,088,866 shares available for grant under the 2019 Omnibus Equity Incentive Plan.